ABVC Biopharma Files 8-K/A Amendment
Ticker: ABVC · Form: 8-K/A · Filed: Jun 25, 2024 · CIK: 1173313
| Field | Detail |
|---|---|
| Company | Abvc Biopharma, Inc. (ABVC) |
| Form Type | 8-K/A |
| Filed Date | Jun 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $3,500,000, $50,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, filing-update, definitive-agreement
TL;DR
ABVC Bio amended an 8-K filing from Nov 2023, mostly procedural stuff, no new bombshells.
AI Summary
ABVC Biopharma, Inc. filed an amendment (8-K/A) on June 25, 2024, to a previous Form 8-K dated November 16, 2023. This amendment pertains to the entry into a material definitive agreement and includes financial statements and exhibits. The filing does not provide new details on the agreement itself but serves as an update to the original report.
Why It Matters
This filing is an amendment to a previous report, indicating a procedural update rather than new material information about a definitive agreement or financial performance.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and does not introduce new material definitive agreements or financial information, suggesting a low immediate risk impact.
Key Players & Entities
- ABVC BIOPHARMA, INC. (company) — Registrant
- November 16, 2023 (date) — Date of earliest event reported
- June 25, 2024 (date) — Date of report
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing is an amendment to a previously filed Form 8-K, specifically addressing the entry into a material definitive agreement and including financial statements and exhibits.
When was the original event reported that this 8-K/A amends?
The original event was reported on November 16, 2023, and this amendment is dated June 25, 2024.
What specific material definitive agreement is being amended or updated?
The filing indicates an amendment related to the 'Entry into a Material Definitive Agreement' and 'Financial Statements and Exhibits' but does not specify the details of the agreement itself within the provided text.
What is ABVC Biopharma, Inc.'s state of incorporation?
ABVC Biopharma, Inc. is incorporated in Nevada.
What is the company's primary business as indicated by its SIC code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 670 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2024-06-25 17:15:10
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Mar
- $3,500,000 — cond milestone payment in the amount of $3,500,000 per Licensing Agreement, incrementally
- $50,000 — nsing Agreement, incrementally (such as $50,000), at any given time, rather than in one
Filing Documents
- ea0208453-8ka1_abvcbio.htm (8-K/A) — 27KB
- ea020845301ex10-1_abvcbio.htm (EX-10.1) — 10KB
- ea020845301ex10-2_abvcbio.htm (EX-10.2) — 10KB
- 0001213900-24-055809.txt ( ) — 222KB
- abvc-20231116.xsd (EX-101.SCH) — 3KB
- abvc-20231116_lab.xml (EX-101.LAB) — 33KB
- abvc-20231116_pre.xml (EX-101.PRE) — 22KB
- ea0208453-8ka1_abvcbio_htm.xml (XML) — 4KB
01 Entry into Material Definitive Agreements
Item 1.01 Entry into Material Definitive Agreements On November 12, 2023, ABVC BioPharma, Inc. (the " Company "), and one of its subsidiaries, BioLite, Inc. (" BioLite "), filed the initial Current Report on Form 8-K to disclose that it entered into a definitive agreement with AiBtl BioPharma Inc. (" AIBL "), pursuant to which the Company and BioLite entered into a multi-year, global licensing agreement (the " Licensing Agreement ") for the Company and BioLite's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (collectively, the " Licensed Products "). On June 23, 2024, the Company and BioLite, each entered into an amendment (the " Amendment ") to the Licensing Agreement with AIBL, pursuant to which the Company and BioLite have agreed to allow AIBL to pay the second milestone payment in the amount of $3,500,000 per Licensing Agreement, incrementally (such as $50,000), at any given time, rather than in one lump sum. The foregoing descriptions of the agreements are not complete and are qualified in their entirety by reference to the full text of the agreements, copies of which are attached as Exhibit 10.1 and 10.2 to this Current Report on Form 8-K/A and incorporated herein by reference.
01 Financial Statement and Exhibits
Item 9.01 Financial Statement and Exhibits (d) Exhibits Exhibit No. Description 10.1 Amendment to the License Agreement between the Company and AiBtl BioPharma Inc. 10.2 Amendment to the License Agreement between BioLite, Inc. and AiBtl BioPharma Inc. 10.3 License Agreement between the Company and AiBtl BioPharma Inc. (incorporated by reference to Exhibit 10.40 of the Company's Quarterly Report on Form 10-Q, filed on November 15, 2023) 10.4 License Agreement between BioLite, Inc. and AiBtl BioPharma Inc. (incorporated by reference to Exhibit 10.41 of the Company's Quarterly Report on Form 10-Q, filed on November 15, 2023) 104 Cover Page Interactive Data File, formatted in Inline XBRL 1 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABVC BioPharma, Inc. June 25, 2024 By: /s/ Uttam Patil Uttam Patil Chief Executive Officer 2